Navigation Links
Mayo-led study: Drug fails to reduce diarrhea in patients receiving radiation therapy
Date:9/24/2013

ROCHESTER, Minn. -- Sulfasalazine, a drug commonly prescribed to reduce diarrhea in patients with inflammatory bowel disease, does not reduce diarrhea in patients receiving radiation therapy for cancers in the pelvic area a Mayo Clinic-led study has found. The study also found that the medication may be associated with a higher risk of diarrhea than a placebo when used during radiation therapy to the pelvis. The results were presented today at the American Society of Radiation Oncology's (ASTRO's) 55th Annual Meeting in Atlanta.

"Patients receiving radiation therapy in the pelvic region can experience diarrhea which is a negative side effect of the therapy," says the study's lead author Robert Miller, M.D., a radiation oncologist at Mayo Clinic. Dr. Miller says that in previous trials sulfasalazine, which treats bowel inflammation, had been shown to decrease diarrhea in patients during pelvic radiation therapy.

Dr. Miller led a two-year, randomized, double-blind, placebo-controlled phase III clinical trial through the Alliance for Clinical Trials in Oncology to evaluate the effectiveness of sulfasalazine versus placebo in inflammation of the bowel during pelvic radiation therapy. The trial included 87 patients, with 78 patients evaluated for the primary endpoint, which was maximal severity of diarrhea up to six weeks after therapy, based on commonly accepted criteria. Patients enrolled in the study came from 24 institutions in the United States.

Patients received 1,000 milligrams of sulfasalazine or placebo orally, twice each day during radiation therapy and for four weeks after therapy. Patients completed bowel function questionnaires weekly during therapy, afterward for six weeks and at 12 and 24 months after therapy. Health care providers graded each patient on the maximum severity and the duration of maximum severity of diarrhea, rectal bleeding, abdominal cramping, constipation and tenesmus, the sensation of incomplete defecation.

Interim results from the study found a statistically significant excess of grade 3 diarrhea -- passing seven or more stools per day, in patients receiving sulfasalazine versus placebo. The study was halted in May 2013 when researchers determined that it was unlikely sulfasalazine would show benefit.

"While previous research had suggested benefit for sulfasalazine, we were very surprised to find that patients receiving sulfasalazine experienced worse diarrhea than those receiving placebo," Dr. Miller says. "We now know that sulfasalazine will not help patients receiving radiation therapy in the pelvic region avoid diarrhea as a side effect of the therapy." Dr. Miller says the study illustrates the need for large, phase III, randomized controlled trials to better understand which drugs and therapies can help mitigate the negative side effects for patients receiving radiation therapy.


'/>"/>

Contact: Joe Dangor
newsbureau@mayo.edu
504-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Cancer-causing gene alone doesnt trigger pancreatic cancer, Mayo-led study finds
2. Study: Memory problems, emotional stress result in early readmissions of heart patients
3. Study: Redefining the Criteria for ALK Positive Lung Cancer
4. Study: Redefining the criteria for ALK positive lung cancer
5. ACR, SBI on cancer study: More breast cancer screening needed in younger women
6. Study: Disease caused by repeat brain trauma in athletes may affect memory, mood, behavior
7. Study: Many evangelicals are ambivalent about homosexuality and civil unions for gays
8. Study: Heart pump with behind-the-ear power connector
9. Study: Centers throughout the brain work together to make reading possible
10. Study: Taxing sugary beverages not a clear cut strategy to reduce obesity
11. Study: Taxing Sugary Beverages Not a Clear Cut Strategy to Reduce Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... Every winter, someone is killed, injured or ... West Penn Burn Center, part of the Allegheny Health Network, has partnered with ... the “Space Heaters Need Space” campaign. , “Space Heaters Need Space” aims ...
(Date:2/12/2016)... ... February 12, 2016 , ... AssureVest Insurance Group, a locally ... a charity drive that will raise funds earmarked to purchase computers and software for ... School. , “My school is in a low-income area and has more than 60 ...
(Date:2/12/2016)... ... February 12, 2016 , ... Vail knee specialist ... Leaders to Know in 2016 . The list consists of physicians establishing, leading and ... establish this list. , An Ambulatory Surgery Center, also known as an ASC, ...
(Date:2/12/2016)... PA (PRWEB) , ... February 12, 2016 , ... ... families of the Pittsburgh metro area, celebrates the beginning of the latest charity ... children develop social skills through art. Donations to this worthy cause are currently ...
(Date:2/12/2016)... MIAMI, FLA (PRWEB) , ... February 12, 2016 , ... ... free dental implants to their Miami dental office. Beginning in January, Miami Dental ... traditional titanium. Miami Dental Specialists are the first office to be chosen by the ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)...  Clinical Affairs leaders at pharmaceutical organizations are looking to either ... world. While some companies have conducted a significant number of clinical ... countries such as India and ... India are now requiring local clinical trials ... --> China and India ...
(Date:2/12/2016)... 12, 2016 Hypermarcas S.A. ("Hypermarcas") today ... offer (the "Tender Offer") to purchase any and ... amount of its 6.500% Senior Notes due 2021 ... USP5246AAF05) (the "Notes"). In connection with the Tender ... consents (the "Consents") of the holders of the ...
(Date:2/12/2016)... , Feb. 12, 2016 /PRNewswire/ - Demers Ambulances announces its ... to Okaloosa County Emergency Medical ... III ambulances and one LT2 van. Quality Emergency Vehicles in ... is responsible for the sale.  This is the latest in ... , Executive Vice President at Demers. --> Benoit ...
Breaking Medicine Technology: